The drug industry's main lobbying group is kicking out members that don't spend enough on developing new products.

According to new rules from the Pharmaceutical Research and Manufacturers of America that went into effect this week, in order to remain members, drug firms  will have to spend at least 10 percent of their sales on global research and development over three years. They will also need to spend at least $200 million per year on R&D.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.